KAMU Health

What KAMU Health does

KAMU Health Ltd. is a Helsinki-based, privately held digital therapeutics company (founded 2017, 1–10 employees) that develops and markets evidence-based, CE-marked software-and-hardware products for respiratory care. Its flagship offering, KAMU Asthma, combines a clinical-grade mobile spirometer (KAMU Spiro) with a smartphone application (iOS and Android) that measures lung function (FEV1, PEF), tracks respiratory medication intake, monitors symptoms, and incorporates local weather and air-quality forecasts plus crowd-sourced environmental alerts. Performed spirometry is automatically quality-controlled against ATS/ERS guidelines, and the product is marketed as a predictive self-management service capable of flagging lung-condition deterioration so patients can adjust medication or avoid adverse environmental exposures.

The company's technology stack is built around a regulated medical-device platform that integrates with 200+ home-use wearables and measurement devices and exposes an advanced API with SSO, access control, and PDF-based data export for clinicians. KAMU is fully GDPR- and HIPAA-compliant and was co-developed with Helsinki University Hospital (Professor Mika Mäkelä), providing clinical validation in the Nordic market.

KAMU operates a hybrid go-to-market motion: a product-led growth layer through free app downloads on the App Store and Google Play paired with one-time hardware sales (its own e-commerce shop in Finland and Amazon UK), combined with an enterprise field-sales motion targeting healthcare providers, payers, employers, and pharmaceutical companies for remote patient monitoring, payer-benefit integration, and clinical-trial Real-World Data collection. Revenue streams therefore span hardware sales, freemium-to-subscription software, enterprise platform licensing, and pharma data services. The company is presently bootstrapped, with no disclosed venture funding, institutional investors, or parent entities in the available source material.

Name

KAMU Health

Legal name

KAMU Health Ltd.

Website

https://kamuhealth.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

KAMU Health Ltd. is a Helsinki-based digital therapeutics company that develops the CE-marked KAMU Asthma platform — a clinical-grade mobile spirometer plus smartphone app for asthma self-management, remote patient monitoring, and respiratory clinical-trial data collection, serving patients, providers, payers, and pharma.

Ownership category

akta.pro rank

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Hardware Sales (KAMU Spirometer): Sale of the clinical-grade mobile spirometer device (KAMU Spiro) through own e-commerce shop, Amazon, and other retail channels.
2. Software/Subscription Services: Mobile app with premium features for asthma management, medication tracking, and remote monitoring. Free download with premium service tiers for healthcare providers and payers.
3. Enterprise Healthcare Solutions: Platform licensing and API access for healthcare providers, payers, and pharmaceutical companies for clinical trial support and patient monitoring.
4. Research & Pharma Data Services: Quality-controlled patient reported outcomes collection for clinical trials, providing Real-World Data for pharmaceutical research.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

KAMU Health develops and markets KAMU Asthma, a CE-marked medical-grade digital therapeutic service that combines a clinical-grade mobile spirometer (KAMU Spiro) with a smartphone app to enable asthma patients to measure lung function, monitor symptoms, track medication adherence, and receive environmental and predictive health alerts. The platform also serves healthcare providers, payers, employers, and pharmaceutical companies through remote patient monitoring, advanced API integrations, and quality-controlled Patient Reported Outcomes collection for clinical trials.

Product overview

KAMU Health offers a unified digital therapeutics platform for respiratory care, consisting of the KAMU Asthma mobile app (available on iOS and Android) paired with the KAMU Spiro hardware device. The platform enables patients to measure lung function with a clinical-grade mobile spirometer, monitor symptoms and medication, and receive predictive alerts based on environmental factors like air quality. Data can be shared with healthcare providers and researchers. The service is available for direct download (app store) and purchase through KAMU's own shop and Amazon.

Differentiator

Problem solved

Functional benefit

Brands

• KAMU Asthma: A predictive self-management service for asthma, CE-marked medical device with mobile spirometer and smartphone app for monitoring lung function, medication, and symptoms.

Products and services

• KAMU Asthma An evidence-based, CE-marked medical device digital therapeutic service for asthma patients and healthcare professionals. The service combines a clinical-grade mobile spirometer with a smartphone app to enable lung function measurements (FEV1, PEF), medication tracking, symptom monitoring, and environmental alerts. It supports remote patient monitoring and self-care report sharing between patients and providers.
• KAMU Spiro A clinical-grade mobile spirometer hardware device that connects to smartphones to measure lung function (FEV1, PEF). Performed tests are automatically quality-controlled per ATS/ERS guidelines, providing reliable measurements for personal asthma management and clinical use.

Quantifiable outcome

• 72% reduction in care costs per patient
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• 200+ Home Use Wearable ManufacturerscoreTechnology or IntegrationPlatform provides access to data from 200+ home use wearables and measurement devices, enabling comprehensive patient monitoring and integration with existing consumer health devices.
• Helsinki University HospitalcoreStrategic or Co-development PartnerCollaborative development of KAMU Asthma with Professor Mika Mäkelä and Helsinki University Hospital. The service is developed in collaboration with asthmatics and doctors, with healthcare provider endorsement for clinical use.
• Healthcare Providers (General)coreImplementation/ SI/ Consulting PartnerDeployment of KAMU Asthma for remote patient monitoring, enabling quality-controlled measurements, symptoms and medication tracking, with data sharing capabilities for healthcare professionals.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Adherium: Adherium develops smart inhaler sensors and a connected respiratory platform for asthma and COPD management, with FDA-cleared devices and pharmaceutical partnerships. It is directly comparable to KAMU's remote monitoring of inhaler-using respiratory patients and its pharma R&D data services.
• NuvoAir: NuvoAir is a European-based respiratory digital health company offering home spirometry, virtual care and remote patient monitoring for asthma, COPD, and other chronic respiratory conditions. Like KAMU, it pairs a connected device with an app and targets healthcare providers and payers across Europe.
• Propeller Health: Propeller Health (acquired by ResMed) is a leading digital health platform for asthma and COPD that attaches sensors to inhalers and provides an app for medication adherence and symptom tracking. It is the most direct comparable to KAMU in respiratory digital therapeutics and serves the same patient, provider, and payer stakeholders.
• Cohero Health: Cohero Health offers connected inhaler sensors and a respiratory digital health platform for asthma and COPD patients, targeting providers and payers. It overlaps directly with KAMU's RPM and medication adherence functionality for respiratory chronic disease.
• Respiri: Respiri (now Aware) develops wheeze detection and respiratory monitoring technologies for asthma management. It competes with KAMU in the consumer and clinical respiratory monitoring category, particularly through connected devices and patient apps.

Emerging players

• WellDoc: WellDoc is a digital therapeutics company focused on chronic disease self-management, with FDA-cleared products for diabetes and partnerships spanning cardiovascular and other chronic conditions. It is comparable to KAMU as a chronic-care digital therapeutic platform pursuing enterprise and payer channels.
• Smart Respiratory Products: Smart Respiratory Products produces connected spirometers and peak flow meters aimed at asthma and COPD self-management. It overlaps with KAMU's mobile-spirometer-plus-app concept but is a smaller emerging competitor with narrower geographic reach.
• Amiko: Amiko develops connected respiratory inhaler sensors and AI-driven adherence analytics for asthma and COPD. It overlaps with KAMU's connected-device-plus-software approach and its pharma RWD value proposition, though with a different hardware form factor.

Broad incumbents

• Teva Pharmaceutical Industries: Teva has launched Digihaler, a portfolio of FDA-approved connected inhalers with companion apps for asthma and COPD. As a global pharmaceutical incumbent with proprietary drug-device combinations, Teva represents a broad incumbent competitor that bundles digital respiratory tools with its inhaler franchises.
• AstraZeneca: AstraZeneca is a major respiratory pharma player that has invested heavily in digital health partnerships for asthma and COPD, including remote monitoring and patient support programs. It is comparable as a deep-pocketed incumbent that competes for the same payer and provider respiratory budgets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/kamuhealth

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KAMU Health